Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, United States.
Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, United States; Department of Biostatistics, Harvard T.H. Chan School of Public Health, Boston, MA, United States.
Crit Rev Oncol Hematol. 2018 Dec;132:66-75. doi: 10.1016/j.critrevonc.2018.09.013. Epub 2018 Sep 29.
Previous studies found divergent effects of aspirin use on prostate cancer incidence, potentially due to studies with short durations of aspirin use and insufficient adjustment for screening.
A systematic review on the association between aspirin use ≥3 years and incident prostate cancer was performed in accordance with the PRISMA and MOOSE criteria.
In the cohort studies, aspirin use for at least 3 years was associated with a lower incidence rate of prostate cancer (Odds ratio (OR) 0.88, 95% CI 0.80-0.97). No protective association was established for the case-control studies (OR 0.92, 95% CI 0.68-1.23). Subgroup analysis of advanced and aggressive cancers showed a protective association (OR 0.82, 95% CI 0.71-0.94 and OR 0.75, 95% CI 0.61-0.97).
This synthesis of observational studies suggests a potential protective association between long term aspirin use and incident prostate cancer. The current literature is highly heterogenous and suffers from inconsistent aspirin dose definition and measurement.
先前的研究发现，阿司匹林的使用对前列腺癌发病率的影响存在差异，这可能是由于研究中阿司匹林使用时间较短，以及对筛查的调整不足。
按照 PRISMA 和 MOOSE 标准，对阿司匹林使用≥3 年与前列腺癌发病风险之间的关联进行了系统评价。
在队列研究中，至少使用 3 年的阿司匹林与前列腺癌发病率降低相关（比值比（OR）0.88，95%置信区间（CI）0.80-0.97）。病例对照研究未发现保护关联（OR 0.92，95%CI 0.68-1.23）。对晚期和侵袭性癌症的亚组分析显示出保护关联（OR 0.82，95%CI 0.71-0.94 和 OR 0.75，95%CI 0.61-0.97）。
这项观察性研究的综合分析表明，长期使用阿司匹林与前列腺癌发病风险之间可能存在潜在的保护关联。目前的文献高度异质，存在阿司匹林剂量定义和测量不一致的问题。
